A US-based phase 2 trial of an investigational oral GLP-1 called CX11 shows up to 11.5% weight loss and a favorable safety profile among patients living with obesity.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/positive-phase-2-results-new-oral-glp-1-obesity-2026a1000mpj?src=rss
Author :
Publish date : 2026-07-06 04:31:00
Copyright for syndicated content belongs to the linked Source.
